Skip to main content
CTOS 2025 Main banner
Final Program


Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.

Amanda Facklam, PhD

Scientist II
Pyxis Oncology

Dr. Amanda Facklam is a Scientist in the Translational Research group at Pyxis Oncology, located in Boston, MA. She focuses on pre-clinical work for micvotabart pelidotin (MICVO, aka PYX-201), a first-in-concept non-cellular targeting antibody drug conjugate currently being tested in patients in phase 1 monotherapy and phase 1/2 combination with pembrolizumab trials. Amanda obtained a B.S in Biomedical Engineering from Johns Hopkins University and a PhD in Biological Engineering from Massachusetts Institute of Technology.

Poster(s):